

Vittoria Rufini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2895452/publications.pdf>

Version: 2024-02-01

109
papers

3,532
citations

147801

31
h-index

149698

56
g-index

115
all docs

115
docs citations

115
times ranked

3740
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1623-1629.	6.4	6
2	Integration of molecular imaging in the personalized approach of patients with adrenal masses. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.7	4
3	Clinical impact of SARS-CoV-2 infection among patients with vulvar cancer: the Gemelli Vul.Can multidisciplinary team. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 127-132.	2.5	3
4	PET/CT in congenital hyperinsulinism: transforming patient's lives by molecular hybrid imaging.. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 12, 44-53.	1.0	0
5	Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4182-4193.	6.4	10
6	Imaging adrenal medulla. , 2021, , .		0
7	Diagnostic performance of preoperative [18F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3303-3314.	6.4	28
8	68Ga-DOTATOC PET/CT in Pleural Solitary Fibrous Tumors. <i>Clinical Nuclear Medicine</i> , 2021, 46, e336-e338.	1.3	8
9	18F-FDG PET and 18F-FDG PET/CT in Vulvar Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, 125-132.	1.3	27
10	The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1228-1238.	6.4	16
11	The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients. <i>Annals of Nuclear Medicine</i> , 2020, 34, 65-73.	2.2	9
12	Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?. <i>Clinical Nuclear Medicine</i> , 2020, 45, e134-e140.	1.3	9
13	Radiomics in Vulvar Cancer: First Clinical Experience Using ¹⁸ F-FDG PET/CT Images. <i>Journal of Nuclear Medicine</i> , 2019, 60, 199-206.	5.0	22
14	Richter Syndrome Presenting With Colon Localization. <i>Clinical Nuclear Medicine</i> , 2019, 44, e87-e89.	1.3	0
15	Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 387-393.	0.7	0
16	FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). <i>Annals of Nuclear Medicine</i> , 2018, 32, 372-377.	2.2	22
17	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2413-2425.	1.4	223
18	Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report. <i>Pancreas</i> , 2018, 47, e20-e22.	1.1	0

#	ARTICLE	IF	CITATIONS
19	68Ga-DOTATOC PET/CT in Thyroid Metastases of Lung Carcinoid. <i>Clinical Nuclear Medicine</i> , 2018, 43, e492-e494.	1.3	3
20	18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. <i>EJNMMI Research</i> , 2018, 8, 64.	2.5	28
21	Are the simplified methods to estimate Ki in 18F-FDG PET studies feasible in clinical routine? Comparison between three simplified methods. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 190-199.	0.7	1
22	Improved Detection of Minimal Residual Disease by 11C-Methionine PET/CT in a Young Patient With Unusual Extramedullary Presentation of Recurrent Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e130-e134.	1.3	5
23	The Accessory Spleen Is an Important Pitfall of 68Ga-DOTANOC PET/CT in the Workup for Pancreatic Neuroendocrine Neoplasm. <i>Pancreas</i> , 2017, 46, 157-163.	1.1	8
24	Evaluation of Dual-Timepoint ¹⁸ F-FDG PET/CT Imaging for Lymph Node Staging in Vulvar Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1913-1918.	5.0	37
25	Measurement uncertainty and clinical impact of target-to-background ratios derived by interim FDG-PET/CT in Hodgkin lymphoma: reply to Laffon and Martan. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2140-2141.	6.4	3
26	Re. <i>Clinical Nuclear Medicine</i> , 2017, 42, 81.	1.3	0
27	Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients. <i>Oncotarget</i> , 2017, 8, 85263-85275.	1.8	14
28	Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). <i>Annals of Nuclear Medicine</i> , 2016, 30, 588-592.	2.2	37
29	Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography. <i>Pancreas</i> , 2016, 45, 345-354.	1.1	33
30	CD 68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. <i>Cancer Medicine</i> , 2016, 5, 398-406.	2.8	28
31	False-Positive Radioiodine Scans in Thyroid Cancer. , 2016, , 185-204.		1
32	Intrapancreatic Accessory Spleen Detected by 68Ga DOTANOC PET/CT and 99mTc-Colloid SPECT/CT Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2015, 40, 415-418.	1.3	17
33	Physiological Activity of Spinal Cord in Children. <i>Spine</i> , 2015, 40, E647-E652.	2.0	16
34	IMAGING IN ENDOCRINOLOGY: 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. <i>European Journal of Endocrinology</i> , 2015, 173, R115-R130.	3.7	47
35	Multicenter Comparison of 18F-FDG and 68Ga-DOTA-Peptide PET/CT for Pulmonary Carcinoid. <i>Clinical Nuclear Medicine</i> , 2015, 40, e183-e189.	1.3	51
36	Cushing's Syndrome due to a Bronchial ACTH-Secreting Carcinoid Successfully Treated With Radiofrequency Ablation (RFA). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E862-E865.	3.6	13

#	ARTICLE	IF	CITATIONS
37	Primary multifocal lymphoma of peripheral nervous system: Case report and review of the literature. <i>Muscle and Nerve</i> , 2014, 50, 1016-1022.	2.2	30
38	Focal congenital hyperinsulinism managed by medical treatment: a diagnostic algorithm based on molecular genetic screening. <i>Clinical Endocrinology</i> , 2014, 81, 679-688.	2.4	16
39	A Rare Case of Solitary Fibrous Tumor of the Adrenal Gland Detected by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, 475-477.	1.3	14
40	Imaging techniques for the evaluation of cervical cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2014, 28, 741-768.	2.8	48
41	Which imaging technique should we use in the follow up of gynaecological cancer?. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2014, 28, 769-791.	2.8	22
42	Multifocal Head and Neck Paraganglioma Evaluated with Different PET Tracers: Comparison Between Fluorine-18-Fluorodeoxyglucose and Gallium-68-Somatostatin Receptor PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 218-219.	1.0	4
43	18F-DOPA PET/CT revealed synchronous neuroendocrine tumors in two sisters with MEN2A syndrome. <i>Endocrine</i> , 2013, 43, 458-459.	2.3	1
44	A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1682-1691.	6.4	13
45	Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. <i>Clinical and Translational Imaging</i> , 2013, 1, 111-122.	2.1	24
46	Comparison of Different Positron Emission Tomography Tracers in Patients with Recurrent Medullary Thyroid Carcinoma: Our Experience and a Review of the Literature. <i>Recent Results in Cancer Research</i> , 2013, 194, 385-393.	1.8	16
47	A phase II study of sunitinib in advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 692-698.	0.9	21
48	Ruolo della PET-TC nella diagnostica dei tumori endocrini. <i>L Endocrinologo</i> , 2013, 14, 261-268.	0.0	0
49	A Rare Case of Neuroendocrine Tumor of the Middle Ear Detected by Gallium-68-DOTANOC-PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1319-1320.	3.6	7
50	Pulmonary Neuroendocrine Tumor Incidentally Detected by 18F-CH PET/CT. <i>Clinical Nuclear Medicine</i> , 2013, 38, e196-e199.	1.3	14
51	Masking Effect of Chronic Pancreatitis in the Interpretation of Somatostatin Receptor Positron Emission Tomography in Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2013, 42, 726-728.	1.1	7
52	A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 185-186.	1.1	14
53	Multifocal Extra-Adrenal Paraganglioma Evaluated With Different PET Tracers. <i>Clinical Nuclear Medicine</i> , 2013, 38, e458-e462.	1.3	11
54	Usefulness of 18F-FDG PET/CT in an Unusual Case of Solid-Pseudopapillary Pancreatic Tumor in Childhood With Aggressive Behavior. <i>Clinical Nuclear Medicine</i> , 2013, 38, e35-e37.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Markedly Increased 18F-FDG Uptake in a Nonfunctioning Adrenal Adenoma Mimicking Malignancy. <i>Clinical Nuclear Medicine</i> , 2013, 38, e333-e335.	1.3	4
56	A Rare Case of Ectopic Adrenocorticotrophic Hormone Syndrome Caused by a Metastatic Neuroendocrine Tumor of the Pancreas Detected by 68Ga-DOTANOC and 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2013, 38, e306-e308.	1.3	16
57	A Case of Insulinoma Detected by 68Ga-DOTANOC PET/CT and Missed by 18F-Dihydroxyphenylalanine PET/CT. <i>Clinical Nuclear Medicine</i> , 2013, 38, e267-e270.	1.3	11
58	The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas. <i>Hormones</i> , 2013, 12, 58-68.	1.9	16
59	PET and PET/CT imaging in thyroid and adrenal diseases: an update. <i>Hormones</i> , 2013, 12, 327-333.	1.9	11
60	Primary Pancreatic Lymphoma in a Patient with Maturity Onset Diabetes of the Young type 3. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012005.	1.3	2
61	Recurrence in region of spared parotid gland in patient receiving definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A case report. <i>Acta Oncologica</i> , 2012, 51, 1095-1099.	1.8	2
62	PET Imaging in Recurrent Medullary Thyroid Carcinoma. <i>International Journal of Molecular Imaging</i> , 2012, 2012, 1-9.	1.3	42
63	A Rare Case of Synchronous Bilateral Pulmonary Neuroendocrine Tumor Detected by 68Ga-DOTANOC PET/CT. <i>Clinical Nuclear Medicine</i> , 2012, 37, e91-e94.	1.3	1
64	Cardiac Metastases of Ewing Sarcoma Detected by 18F-FDG PET/CT. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 236-238.	0.6	21
65	Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography. <i>Academic Radiology</i> , 2012, 19, 1290-1299.	2.5	64
66	Can "early" and "late" 18F-FDG PET/CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?. <i>Radiotherapy and Oncology</i> , 2012, 103, 63-68.	0.6	70
67	18F-fluoro-deoxy-glucose focal uptake in very small pulmonary nodules: fact or artifact? Case reports. <i>World Journal of Surgical Oncology</i> , 2012, 10, 71.	1.9	5
68	Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. <i>Endocrine</i> , 2012, 42, 535-545.	2.3	77
69	Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. <i>Annals of Nuclear Medicine</i> , 2012, 26, 764-768.	2.2	1
70	Clinical applications of 18F-FDG PET in the management of hepatobiliary and pancreatic tumors. <i>Abdominal Imaging</i> , 2012, 37, 983-1003.	2.0	41
71	Role of PET/CT in the functional imaging of endocrine pancreatic tumors. <i>Abdominal Imaging</i> , 2012, 37, 1004-1020.	2.0	67
72	Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis. <i>Pediatric Radiology</i> , 2012, 42, 1372-1379.	2.0	49

#	ARTICLE	IF	CITATIONS
73	Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer. <i>Hormones</i> , 2012, 11, 230-232.	1.9	9
74	Oncologic outcomes in advanced laryngeal squamous cell carcinomas treated with different modalities in a single institution: A retrospective analysis of 65 cases. <i>Head and Neck</i> , 2012, 34, 573-579.	2.0	26
75	Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. <i>Endocrine</i> , 2012, 42, 80-87.	2.3	239
76	The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. <i>Annals of Nuclear Medicine</i> , 2012, 26, 451-461.	2.2	94
77	Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 569-580.	6.4	136
78	Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1144-1153.	6.4	97
79	Clinical significance of incidental focal colorectal ¹⁸ F-fluorodeoxyglucose uptake: our experience and a review of the literature. <i>Colorectal Disease</i> , 2012, 14, 174-180.	1.4	68
80	18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. <i>Clinical Imaging</i> , 2012, 36, 167-175.	1.5	45
81	Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment?. <i>Cancer</i> , 2012, 118, 392-403.	4.1	36
82	Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. <i>Nuclear Medicine Communications</i> , 2011, 32, 575-582.	1.1	56
83	Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2011, 154, 141-143.	2.5	6
84	Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of ¹³¹ I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1032-1040.	1.5	41
85	Congenital Hyperinsulinism and Glucose Hypersensitivity in Homozygous and Heterozygous Carriers of Kir6.2 (<i>KCNJ11</i>) Mutation V290M Mutation. <i>Diabetes</i> , 2011, 60, 209-217.	0.6	17
86	Renal artery stenting in patients with chronic ischemic heart disease. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 26-34.	1.7	7
87	Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2010, 3, 391-396.	0.7	6
88	Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. <i>Abdominal Imaging</i> , 2009, 34, 391-402.	2.0	57
89	Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. <i>Abdominal Imaging</i> , 2009, 34, 696-711.	2.0	27
90	Ectopic ACTH Syndrome Due to Occult Bronchial Carcinoid. <i>Clinical Nuclear Medicine</i> , 2009, 34, 459-461.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Impact of ¹¹¹ In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. <i>Radiologia Medica</i> , 2008, 113, 1056-1067.	7.7	58
92	Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 139-146.	5.6	51
93	Unusual Increased Metaiodobenzylguanidine Uptake in Liposarcoma. <i>Clinical Nuclear Medicine</i> , 2008, 33, 627-629.	1.3	4
94	Thyroid carcinomas with a variable insular component. <i>Cancer</i> , 2007, 110, 1209-1217.	4.1	31
95	Noninvasive adrenal imaging in hyperaldosteronism: is it accurate for correctly identifying patients who should be selected for surgery?. <i>Langenbeck's Archives of Surgery</i> , 2007, 392, 623-628.	1.9	11
96	Imaging of Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2006, 36, 228-247.	4.6	387
97	False-Positive Radioiodine Scans in Thyroid Cancer. , 2006, , 179-198.		1
98	Are there disadvantages in administering ¹³¹ I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic ¹³¹ I whole-body scan?. <i>Clinical Endocrinology</i> , 2004, 61, 704-710.	2.4	24
99	Unsuspected Testicular Metastases From Merkel Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 636-637.	1.3	8
100	Radio-guided Surgery for Lymph Node Recurrences of Differentiated Thyroid Cancer. <i>World Journal of Surgery</i> , 2003, 27, 770-775.	1.6	54
101	Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type. <i>Cancer</i> , 2001, 92, 2273-2279.	4.1	53
102	Radioresistant sensitization of neuroblastoma by cisplatin?. <i>Medical and Pediatric Oncology</i> , 2000, 35, 77-79.	1.0	7
103	Cystic Medullary Thyroid Carcinoma: Report of a Case with Morphological and Clinical Correlations. <i>Endocrine Pathology</i> , 2000, 11, 373-378.	9.0	10
104	Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body ¹³¹ I scans in patients with thyroid cancer. <i>Seminars in Nuclear Medicine</i> , 2000, 30, 115-132.	4.6	139
105	Optimal use of the ¹³¹ I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. <i>Journal of Neuro-Oncology</i> , 1997, 31, 153-158.	2.9	31
106	Unusual False-Positive Radioiodine Whole-Body Scans in Patients With Differentiated Thyroid Carcinoma. <i>Clinical Nuclear Medicine</i> , 1997, 22, 380-384.	1.3	32
107	Critical observations on neuroblastoma treatment with ¹³¹ I-metaiodobenzylguanidine at diagnosis. <i>Medical and Pediatric Oncology</i> , 1993, 21, 411-415.	1.0	17
108	The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1990, 16, 325-335.	2.1	108

#	ARTICLE	IF	CITATIONS
109	Thyroid carcinoma mimicking a toxic adenoma. European Journal of Nuclear Medicine and Molecular Imaging, 1990, 17, 179-184.	2.1	33